A Study of SHR-1802 in Patients With Advanced Solid Tumor
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in
subjects with advanced solid tumor and to determine the dose-limiting toxicity
(DLT)，recommended phase II dose (RP2D) and assess objective response rate (ORR) assessed by
the investigator based on RECIST v1.1 criteria.